Sugi Predict

Sugi Predict / Compounds / Tizoxanide

Tizoxanide

Tizoxanide

SCHEMBL375440

O=C(Nc1ncc([N+](=O)[O-])s1)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 9/20 1.00
▸ NPC1 O15118 9/20 0.75
▸ RAB9A P51151 9/20 0.75
▸ MEN1 O00255 8/20 0.75
▸ KMT2A Q03164 8/20 0.75
▸ POLB P06746 1/20 0.75
▸ PKM P14618 4/20 0.67
▸ MAPT P10636 4/20 0.67
▸ HTT P42858 3/20 0.67
▸ ALDH1A1 P00352 2/20 0.67
▸ LMNA P02545 2/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ NPSR1 Q6W5P4 2/20 0.67
▸ MLNR O43193 1/20 0.67
▸ NR1I2 O75469 1/20 0.67
▸ ABCB11 O95342 1/20 0.67
▸ TP53 P04637 1/20 0.67
▸ ADRB2 P07550 1/20 0.67
▸ CHRM2 P08172 1/20 0.67
▸ ADRB1 P08588 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tizoxanide SCHEMBL29367981 1.00 STAT3 (1.00) STAT3NPC1RAB9AMEN1KMT2A
Tizoxanide SCHEMBL28425712 0.95 STAT3 (0.91) STAT3NPC1RAB9AMEN1KMT2A
Nitazoxanide SCHEMBL28333130 0.88 STAT3 (0.90) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL11154311 0.88 STAT3 (0.79) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL29056922 0.87 STAT3 (0.77) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL28914964 0.86 STAT3 (0.75) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL30142722 0.86 STAT3 (0.75) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL11160505 0.86 STAT3 (0.80) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL11154084 0.86 STAT3 (0.75) STAT3NPC1RAB9AMEN1KMT2A
SCHEMBL28567553 0.86 NPC1 (1.00) STAT3NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 — — US claimed
US-20260124182-A1 NITAZOXANIDE FOR THE TREATMENT OF HEPATIC IMPAIRMENT GENFIT (FR) 2026-05-07 — — US claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 — — EP claimed
EP-4673157-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME Persephone Biosciences, Inc. (US) 2026-01-07 — — EP claimed
WO-2025264805-A2 SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME PERSEPHONE BIOSCIENCES, INC. (US) 2025-12-26 — — WO claimed
US-12503730-B2 Detectable nucleotide analogues THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-12-23 — — US claimed
US-20250313720-A1 CHEMICAL MECHANICAL POLISHING SLURRY COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE SOULBRAIN CO., LTD. (KR) 2025-10-09 — — US claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 — — US claimed
EP-3952868-B1 COMBINATIONS OF NITAZOXANIDE OR TIZOXANIDE AND ELAFIBRANOR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS- OR PRIMARY SCLEROSING CHOLANGITIS-ASSOCIATED INFLAMMATION GENFIT (FR) 2025-08-13 — — EP claimed
EP-4598525-A1 NITAZOXANIDE FOR THE TREATMENT OF HEPATIC IMPAIRMENT Genfit (FR) 2025-08-13 — — EP claimed
EP-1976516-A2 VIRAL HEPATITIS TREATMENT Romark Laboratories, L.C. (US) 2008-10-08 — — EP claimed
EP-1871365-A2 METHODS FOR TREATING DISEASES THROUGH INHIBITION THE FUNCTION OF MOLECULAR CHAPERONES SUCH AS PROTEIN DISULFIDE ISOMERASES , PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND SCREENING METHODS FOR IDENTIFYING THERAPEUTIC AGENTS Romark Laboratories, L.C. (US) 2008-01-02 — — EP claimed
WO-2007081974-A2 VIRAL HEPATITIS TREATMENT ROMARK LABORATORIES, L.C. (US) 2007-07-19 — — WO claimed
US-20070167504-A1 Viral hepatitis treatment U.S. BANK NATIONAL ASSOCIATION 2007-07-19 — — US claimed
US-20070015803-A1 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents ROMARK LABORATORIES L.C. 2007-01-18 — — US claimed
WO-2006110814-A2 METHODS FOR TREATING DISEASES THROUGH INHIBITION THE FUNCTION OF MOLECULAR CHAPERONES SUCH AS PROTEIN DISULFIDE ISOMERASES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND SCREENING METHODS FOR IDENTIFYING THERAPEUTIC AGENTS ROMARK LABORATORIES, L.C. (US) 2006-10-19 — — WO claimed
US-20060194853-A1 Alkyl benzamides LAMINAR DIRECT CAPITAL, L.L.C. 2006-08-31 — — US claimed
WO-2006042195-A1 ALKYL BENZAMIDES ROMARK LABORATORIES, L.C. (US) 2006-04-20 — — WO claimed
WO-2000002559-A1 SYNTHESIS OF ARYL GLUCURONIDE OF 2-HYDROXY-N-(5-NITRO-2-THIAZOLYL) BENZAMIDE, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME ROMARK LABORATORIES, L.C. (US) 2000-01-20 — — WO claimed
US-5925622-A Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same ROMARK LABORATORIES, L.C. (US) 1999-07-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015803-A1 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents HSP90B1, HSPA5, P4HB STAT3 3390/4885NPC1 999/4885RAB9A 2688/4885
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS ACE, MAVS, SARS1 STAT3 1252/4885NPC1 798/4885RAB9A 589/4885
US-20260124182-A1 NITAZOXANIDE FOR THE TREATMENT OF HEPATIC IMPAIRMENT CYP3A5, UGT1A9, UGT1A3 STAT3 1140/4885NPC1 502/4885RAB9A 2216/4885
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT ZFX, ACE2, ZFR STAT3 523/4885NPC1 3331/4885RAB9A 3239/4885
US-20060194853-A1 Alkyl benzamides SAMHD1, PIGS, BTD STAT3 2811/4885NPC1 669/4885RAB9A 1728/4885
US-20070167504-A1 Viral hepatitis treatment HAVCR2, PYGL, SLC10A1 STAT3 708/4885NPC1 1773/4885RAB9A 2525/4885
US-12503730-B2 Detectable nucleotide analogues NT5C3B, NUDT1, RNGTT STAT3 4296/4885NPC1 666/4885RAB9A 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.